Despite the controversy surrounding its expression levels, OGA’s status as a potential tauopathy target became more convincing when studies revealed that the oral administration of an OGA inhibitor thiamet-G to Sprague Dawley rats effectively reduced their brain tau phosphorylation level in vivo [142]. The gene discussed is OGA; the disease is tauopathy.